Literature DB >> 15153442

Somatostatin receptor targeting for tumor imaging and therapy.

Carsten Grötzinger1, Bertram Wiedenmann.   

Abstract

Somatostatin receptors and their ligands constitute the prototype targeting system for contrast-enhanced detection and radiotherapy of cancer. Radiolabeled synthetic analogs of somatostatin have been successfully used in routine molecular imaging of primary gastroenteropancreatic neuroendocrine tumors and their metastases for more than 15 years. Likewise, analog conjugates for radiation therapy have been developed and have been under clinical trial for several years. The vast amount of knowledge accumulated by both basic and clinical science has made the somatostatin/somatostatin receptor system a popular model for new targeting strategies in imaging and therapy. Among those, the use of near-infrared fluorescent dye-peptide conjugates for the detection of tumors by endoscopy, mammography, or intraoperative imaging is one of the most promising. This article reviews recent developments in the field and discusses concepts for receptor-targeted molecular imaging and therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15153442     DOI: 10.1196/annals.1294.028

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  2 in total

1.  Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines.

Authors:  Samantha Exner; Vikas Prasad; Bertram Wiedenmann; Carsten Grötzinger
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-06       Impact factor: 5.555

Review 2.  Site-Selective Disulfide Modification of Proteins: Expanding Diversity beyond the Proteome.

Authors:  Seah Ling Kuan; Tao Wang; Tanja Weil
Journal:  Chemistry       Date:  2016-10-25       Impact factor: 5.236

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.